Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies
Datamatics will automate the Medication Administration Record process by integrating its intelligent automation products, TruBot and TruCap+
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Subscribe To Our Newsletter & Stay Updated
